We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Inogen (INGN) Surges 6.9%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Inogen (INGN - Free Report) shares ended the last trading session 6.9% higher at $6.8. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 'no gain, no loss' position over the past four weeks.
The sharp rise in INGN shares can be attributed to a bullish initiation by Freedom Broker, which assigned a “Buy” rating and a price target implying significant upside, drawing fresh investor attention to the underfollowed stock. Sentiment was further supported by governance improvements, including the appointment of industry veteran Vafa Jamali to the board and a cooperation agreement with activist shareholder Kent Lake, signaling greater strategic alignment and execution oversight.
This produces oxygen concentrators for patients suffering from chronic respiratory conditions is expected to post quarterly loss of $0.24 per share in its upcoming report, which represents a year-over-year change of +4%. Revenues are expected to be $82.4 million, up 0.2% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Inogen, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on INGN going forward to see if this recent jump can turn into more strength down the road.
Inogen is a member of the Zacks Medical - Instruments industry. One other stock in the same industry, PROCEPT BioRobotics Corporation (PRCT - Free Report) , finished the last trading session 2.5% lower at $23.19. PRCT has returned -5.9% over the past month.
For PROCEPT BIOROBO, the consensus EPS estimate for the upcoming report has changed -16.7% over the past month to -$0.55. This represents a change of -22.2% from what the company reported a year ago. PROCEPT BIOROBO currently has a Zacks Rank of #4 (Sell).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Inogen (INGN) Surges 6.9%: Is This an Indication of Further Gains?
Inogen (INGN - Free Report) shares ended the last trading session 6.9% higher at $6.8. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 'no gain, no loss' position over the past four weeks.
The sharp rise in INGN shares can be attributed to a bullish initiation by Freedom Broker, which assigned a “Buy” rating and a price target implying significant upside, drawing fresh investor attention to the underfollowed stock. Sentiment was further supported by governance improvements, including the appointment of industry veteran Vafa Jamali to the board and a cooperation agreement with activist shareholder Kent Lake, signaling greater strategic alignment and execution oversight.
This produces oxygen concentrators for patients suffering from chronic respiratory conditions is expected to post quarterly loss of $0.24 per share in its upcoming report, which represents a year-over-year change of +4%. Revenues are expected to be $82.4 million, up 0.2% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Inogen, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on INGN going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Inogen is a member of the Zacks Medical - Instruments industry. One other stock in the same industry, PROCEPT BioRobotics Corporation (PRCT - Free Report) , finished the last trading session 2.5% lower at $23.19. PRCT has returned -5.9% over the past month.
For PROCEPT BIOROBO, the consensus EPS estimate for the upcoming report has changed -16.7% over the past month to -$0.55. This represents a change of -22.2% from what the company reported a year ago. PROCEPT BIOROBO currently has a Zacks Rank of #4 (Sell).